Insilico Medicine has signed a deal worth up to $600 million with Japanese Big Pharma Takeda to collaborate on discovery of assets across Takeda’s therapeutic areas of interest.
Insilico keeps partnership sprint apace in $600M biobucks collab with Takeda
Post navigation
Previous Post
Mapping Human Stem Cells with Genome-Scale CRISPRi